Header Logo

Connection

CHRISTIE BALLANTYNE to Lipids

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Lipids.
CHRISTIE BALLANTYNE
Connection Strength
5.206
Lipids
  1. Genetic testing in hyperlipidemia. Cardiol Clin. 2015 May; 33(2):267-75.
    View in: PubMed
    Score: 0.390
  2. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014 Oct; 11(10):563-75.
    View in: PubMed
    Score: 0.367
  3. Lipids and CVD management: towards a global consensus. Eur Heart J. 2005 Nov; 26(21):2224-31.
    View in: PubMed
    Score: 0.197
  4. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004 Sep; 6(5):353-62.
    View in: PubMed
    Score: 0.186
  5. NLA/ASPC response to the USPSTF recommendation statement on screening lipid panel in children and adolescents. J Clin Lipidol. 2023 Sep-Oct; 17(5):559-560.
    View in: PubMed
    Score: 0.175
  6. Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care? J Am Coll Cardiol. 2023 04 11; 81(14):1350-1352.
    View in: PubMed
    Score: 0.169
  7. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
    View in: PubMed
    Score: 0.168
  8. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep. 2021 07 16; 23(9):116.
    View in: PubMed
    Score: 0.150
  9. Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2021 03; 41(3):1229-1238.
    View in: PubMed
    Score: 0.145
  10. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000 Jan; 35(1):89-95.
    View in: PubMed
    Score: 0.135
  11. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.135
  12. Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nat Commun. 2019 Nov 12; 10(1):5121.
    View in: PubMed
    Score: 0.133
  13. Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. Am J Epidemiol. 2019 Jun 01; 188(6):1033-1054.
    View in: PubMed
    Score: 0.129
  14. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.129
  15. Statin use in carnitine palmitoyltransferase II deficiency. J Clin Lipidol. 2019 Jul - Aug; 13(4):550-553.
    View in: PubMed
    Score: 0.129
  16. Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet. 2019 Apr; 51(4):636-648.
    View in: PubMed
    Score: 0.128
  17. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol. 1997 Dec; 8(6):354-61.
    View in: PubMed
    Score: 0.117
  18. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.111
  19. Serum vitamin D and change in lipid levels over 5?y: The Atherosclerosis Risk in Communities study. Nutrition. 2017 Jun; 38:85-93.
    View in: PubMed
    Score: 0.110
  20. Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS One. 2016; 11(2):e0148765.
    View in: PubMed
    Score: 0.103
  21. Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2015 Oct; 242(2):625-9.
    View in: PubMed
    Score: 0.100
  22. The world and lipidology as it relates to cardiology. Cardiol Clin. 2015 May; 33(2):xiii-xiv.
    View in: PubMed
    Score: 0.097
  23. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metab Syndr Relat Disord. 2015 Aug; 13(6):239-47.
    View in: PubMed
    Score: 0.097
  24. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan; 175(1):138-40.
    View in: PubMed
    Score: 0.095
  25. Decrease the incentives to order lipid panels--reply. JAMA Intern Med. 2014 Mar; 174(3):473-4.
    View in: PubMed
    Score: 0.090
  26. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
    View in: PubMed
    Score: 0.088
  27. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
    View in: PubMed
    Score: 0.088
  28. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.087
  29. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet. 2012 Nov 02; 91(5):823-38.
    View in: PubMed
    Score: 0.082
  30. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012 Feb; 5(1):155-62.
    View in: PubMed
    Score: 0.077
  31. Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):73-80.
    View in: PubMed
    Score: 0.077
  32. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011 Feb; 32(4):459-68.
    View in: PubMed
    Score: 0.071
  33. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010 Aug 05; 466(7307):707-13.
    View in: PubMed
    Score: 0.070
  34. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
    View in: PubMed
    Score: 0.065
  35. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res. 2009 Aug; 50(8):1685-91.
    View in: PubMed
    Score: 0.064
  36. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics. 2004 Jan; 14(1):61-71.
    View in: PubMed
    Score: 0.044
  37. Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease. JAMA Netw Open. 2023 03 01; 6(3):e234709.
    View in: PubMed
    Score: 0.042
  38. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 Mar; 34(3):623-31.
    View in: PubMed
    Score: 0.042
  39. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl). 2002 11; 80(11):737-44.
    View in: PubMed
    Score: 0.041
  40. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 04; 104(10):1108-13.
    View in: PubMed
    Score: 0.038
  41. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001 Aug 01; 88(3):265-9.
    View in: PubMed
    Score: 0.038
  42. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001 May 11; 88(9):969-73.
    View in: PubMed
    Score: 0.037
  43. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 2001 Feb 15; 154(3):633-40.
    View in: PubMed
    Score: 0.036
  44. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019 Aug; 131(6):390-396.
    View in: PubMed
    Score: 0.033
  45. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
    View in: PubMed
    Score: 0.032
  46. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.032
  47. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.029
  48. Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPAR?. Nat Commun. 2017 04 10; 8:14960.
    View in: PubMed
    Score: 0.028
  49. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.023
  50. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 1992 May; 19(6):1315-21.
    View in: PubMed
    Score: 0.020
  51. Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities. Magn Reson Imaging. 2011 Oct; 29(8):1065-75.
    View in: PubMed
    Score: 0.019
  52. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
    View in: PubMed
    Score: 0.018
  53. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44.
    View in: PubMed
    Score: 0.017
  54. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010 May; 30(5):1034-42.
    View in: PubMed
    Score: 0.017
  55. Correlates of carotid plaque presence and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Imaging. 2009 Jul; 2(4):314-22.
    View in: PubMed
    Score: 0.016
  56. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov; 26(4):547-60.
    View in: PubMed
    Score: 0.016
  57. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec; 26(24):2664-72.
    View in: PubMed
    Score: 0.012
  58. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
    View in: PubMed
    Score: 0.009
  59. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl). 2000; 78(10):562-8.
    View in: PubMed
    Score: 0.008
  60. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.